Akari Therapeutics, Plc

NasdaqCM AKTX

Akari Therapeutics, Plc Price to Sales Ratio (P/S) on December 19, 2024

Akari Therapeutics, Plc Price to Sales Ratio (P/S) is NA on December 19, 2024, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Akari Therapeutics, Plc 52-week high Price to Sales Ratio (P/S) is NA on December 19, 2024, which is NA below the current Price to Sales Ratio (P/S).
Akari Therapeutics, Plc 52-week low Price to Sales Ratio (P/S) is NA on December 19, 2024, which is NA below the current Price to Sales Ratio (P/S).
Akari Therapeutics, Plc average Price to Sales Ratio (P/S) for the last 52 weeks is NA.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: AKTX

Akari Therapeutics, Plc

CEO	Dr. Samir Rashmikant Patel M.D.
IPO Date	Jan. 6, 2014
Location	United Kingdom
Headquarters	75/76 Wimpole Street
Employees	6
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Key trends

Past 5 years